MET positive

P1, N=36, Not yet recruiting, Peking Union Medical College Hospital; Ruitherapeutics Co., LTD

P1, N=112, Not yet recruiting, TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.

Critically, in fluorescence-guided surgical navigation studies, the probe accurately delineated tumor margins from adjacent normal tissues and effectively identified residual microfoci, thereby facilitating the complete resection of malignant tumors in xenograft models and orthotopic settings. These findings identified that GM-7-MPA was a promising candidate for the diagnosis and surgical navigation of c-Met positive HCC, demonstrating significant translational potential and clinical application prospects.

P1, N=67, Completed, RemeGen Co., Ltd. | N=32 --> 67 | Trial primary completion date: May 2025 --> Dec 2025 | Active, not recruiting --> Completed

P2, N=29, Completed, RemeGen Co., Ltd. | Active, not recruiting --> Completed | N=240 --> 29

As these alterations are druggable in other cancers, early molecular testing may identify MET-positive ATCs eligible for anti-MET therapies in clinical trials. We recommend RNA-based sequencing and FISH as biomarker assays to identify MET alterations.

C-met positive expression indicates a poor prognosis in esophageal cancer patients. Further studies are required to confirm our result.

P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026

[68Ga]Ga-NOTA-PFCM01 showed a specific and high tumor uptake in c-Met-positive PDAC models, providing a noninvasive method to assess c-Met expression. Besides, it demonstrated good pharmacokinetic characteristics in non-human primates. Therefore, [68Ga]Ga-NOTA-PFCM01 provided the potential role as a prospective PET imaging agent for future clinical applications.

P1, N=31, Completed, Byondis B.V. | Active, not recruiting --> Completed

In conclusion, B7-H3 is a promising drug developing target for PCa; however, c-MET may be limited by its low expression in tumor site while relative higher expression in peri-tumor site in PCa. Further investigation is warranted regarding bi-specific drugs for B7-H3 and another marker.

Five ADCs were evaluated: trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1), telisotuzumab vedotin, patritumab deruxtecan, and datopotamab deruxtecan (Dato-DXd)...Dato-DXd demonstrated improved ORR (26.4% vs. 12.8%) and PFS (4.4 vs. 3.7 months) compared to docetaxel...While ADCs offer significant clinical benefits, careful patient selection and proactive management of adverse events remain crucial. Ongoing and future trials will further refine the role of ADCs in personalized NSCLC treatment, potentially expanding their tumor-agnostic use to broader patient populations.